Palvella Reports Positive Phase 3 Data for QTORIN Gel

The latest update is out from Palvella Therapeutics ( (PVLA) ).

On February 24, 2026, Palvella Therapeutics presented topline Phase 3 SELVA data for its QTORIN 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations, a serious, progressive condition with no FDA-approved therapies and an estimated 30,000 diagnosed patients in the U.S. The study showed highly statistically significant improvement on the primary mLM-IGA endpoint, with a mean +2.13 change at Week 24 and 86% of evaluable participants rated “much” or “very much” improved.

The trial also met key secondary endpoints, demonstrating significant gains across vesicle appearance, lesion height, and leaking or bleeding, with a safety profile described as well-tolerated in both adult and pediatric patients, supporting chronic administration. Nearly all Week 24 completers (98%) rolled into the extension period, and the strength of these results underpins Palvella’s plan to move rapidly toward a U.S. regulatory filing, potentially positioning QTORIN as the first approved therapy for this indication and reinforcing the company’s strategy in the rare dermatologic and vascular malformation market.

The most recent analyst rating on (PVLA) stock is a Buy with a $205.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Spark’s Take on PVLA Stock

According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.

The score is held down primarily by weak financial performance (no current revenue, ongoing losses, and persistent cash burn) and bearish technical signals. Offsetting this, corporate events are notably positive with encouraging Phase 2 data and clear near-term clinical/regulatory catalysts, but this does not fully overcome the current fundamentals and trend.

To see Spark’s full report on PVLA stock, click here.

More about Palvella Therapeutics

Palvella Therapeutics, Inc. is a rare disease biopharmaceutical company focused on developing and commercializing first-in-disease therapies for serious, rare skin diseases and vascular malformations. Its lead program, QTORIN 3.9% rapamycin anhydrous gel, is designed as a targeted mTOR inhibitor with deep dermal penetration and sustained retention, optimized for chronic use in both pediatric and adult patient populations with high unmet medical need.

Average Trading Volume: 274,863

Technical Sentiment Signal: Buy

Current Market Cap: $942.2M

For detailed information about PVLA stock, go to TipRanks’ Stock Analysis page.